Achieve Life Sciences grants options and RSUs to director

Achieve Life Sciences, Inc. granted director Jeffrey S. Farrow equity awards consisting of 25,000 stock options to buy common stock at an exercise price of $6.18 per share, expiring July 27, 2036, and 16,700 RSUs.

Rhea-AI Filing Summary

Achieve Life Sciences, Inc. granted director Jeffrey S. Farrow equity awards consisting of 25,000 stock options to buy common stock at an exercise price of $6.18 per share, expiring July 27, 2036, and 16,700 RSUs. Both the options and RSUs vest 100% on the earlier of July 27, 2027 or the date immediately prior to the company’s 2027 annual meeting of stockholders, subject to Farrow’s continued service.

Insider Trade Summary

Grant/Award: 41,700 shares

Grant/Award 2 txns

Insider Farrow Jeffrey S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	25,000	$0.00	$0.00
Grant/Award	Restricted Stock Unit (RSU) F2, F3	16,700	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct); Restricted Stock Unit (RSU) — 16,700 contracts (Direct)

Footnotes (3)

1. F1. The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.
3. F3. Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

Key Figures

Stock options granted: 25,000 shares Option exercise price: $6.18 per share Option expiration date: July 27, 2036 +2 more

5 metrics

Stock options granted 25,000 shares Director equity option award on July 27, 2026

Option exercise price $6.18 per share Exercise price for 25,000 stock options granted to director

Option expiration date July 27, 2036 Expiration of stock options granted to Jeffrey S. Farrow

RSUs granted 16,700 units Restricted Stock Unit award to director on July 27, 2026

Vesting reference date July 27, 2027 Earlier of this date or immediately before 2027 annual meeting for 100% vesting

Key Terms

Restricted Stock Unit (RSU), Stock Option (right to buy), vesting, contingent right

4 terms

Restricted Stock Unit (RSU) financial

"Restricted Stock Unit (RSU) represents a contingent right to receive one share"

A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of $6.18 per share"

vesting financial

"The options vest 100% on the earlier of July 27, 2027 or prior to the 2027 meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

contingent right financial

"Each RSU represents a contingent right to receive one share of common stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ACHV director Jeffrey S. Farrow report?

Jeffrey S. Farrow reported two equity award grants: stock options for 25,000 shares at a $6.18 exercise price and 16,700 restricted stock units (RSUs). Both awards are held directly and represent new grants, not market purchases or sales.

What are the key terms of Jeffrey S. Farrow’s ACHV stock option grant?

Farrow received 25,000 stock options to buy Achieve Life Sciences common stock at $6.18 per share, expiring on July 27, 2036. The options vest 100% on the earlier of July 27, 2027 or immediately before the 2027 annual stockholders’ meeting, contingent on continued service.

What are the details of Jeffrey S. Farrow’s RSU award from ACHV?

Farrow was granted 16,700 RSUs, each representing a contingent right to receive one share of Achieve Life Sciences common stock. The RSUs vest 100% on the earlier of July 27, 2027 or immediately before the 2027 annual meeting, subject to his continued service with the company.

Do Jeffrey S. Farrow’s ACHV Form 4 transactions involve open-market buying or selling?

No. The Form 4 for ACHV shows only grant/award acquisitions (code A) of stock options and RSUs to Jeffrey S. Farrow. There are no reported open-market purchases or sales of Achieve Life Sciences common stock in this filing.

When will Jeffrey S. Farrow’s new ACHV equity awards fully vest?

Both the 25,000 stock options and 16,700 RSUs granted to Farrow vest 100% on the earlier of July 27, 2027 or the date immediately prior to Achieve Life Sciences’ 2027 annual meeting, provided he continues to serve the company through the vesting date.

How many ACHV shares could Jeffrey S. Farrow ultimately receive from these awards?

If fully vested and exercised/settled, Farrow’s new awards cover 25,000 shares from stock options plus 16,700 shares from RSUs, totaling 41,700 shares of Achieve Life Sciences common stock, all subject to vesting and, for options, payment of the exercise price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 05:19 PM Accepted by SEC EDGAR 07/29/2026 - 05:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrow Jeffrey S

(Last) (First) (Middle)

22722 29TH DR. SE

SUITE 100

(Street)

BOTHELL WASHINGTON 98021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACHIEVE LIFE SCIENCES, INC. [ ACHV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.18	07/27/2026		A		25,000		(1)	07/27/2036	Common Stock	25,000	$0	25,000	D
Restricted Stock Unit (RSU)	(2)	07/27/2026		A		16,700		(3)	07/27/2036	Common Stock	16,700	$0	16,700	D

Explanation of Responses:

1. The options vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock at settlement.

3. Pursuant to the terms of the RSU, the shares underlying the RSU vest 100% on the earlier of July 27, 2027 or the date immediately prior to the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

	Sandra Thomson as attorney-in-fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)